eculizumab
Soliris	Pharmaceutical company: Alexion Pharmaceuticals www.alexionpharm.com

Pharmacologic classification: monoclonal antibody
Therapeutic classification: complement inhibitor
Pregnancy risk category: C

AVAILABLE FORMS
Single-use vials: 10 mg/ml

INDICATIONS AND DOSAGES
Reduce hemolysis in patients with paroxysmal nocturnal hemoglobinuria--
Adults: Initially, 600 mg I.V. over 35 minutes q week for 4 weeks; then, in week 5 give 900 mg I.V., followed by 900 mg I.V. q 2 weeks.

CONTRAINDICATIONS AND CAUTIONS
Contraindicated in patients with unresolved, serious Neisseria meningitides infection, and in those who aren’t currently immunized against N. meningitides.
   Use cautiously in patients with systemic infection and in pregnant or breast-feeding women.

INTERACTIONS
None reported.

ADVERSE REACTIONS
CNS: headache, fatigue, fever.
GI: nausea, constipation.
Respiratory: nasopharyngitis, cough, sinusitis, respiratory tract infection.
Other: back pain, herpes simplex infections, myalgia, extremity pain, flulike illness, viral infection, anemia.

Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our Disclaimer .

© Copyright 2008 by Lippincott Williams & Wilkins